low otherVERIFIED
GLP-1 weight-loss pills expand to China as US firm wins approval
Verified: 3 outlets in 2 countries have reported this story since Nov 12.
📍 China, CN·🕐 1h ago·3 outlets
How sure are we
✓ Verified · 3 outlets
Two or more outlets reported this story and its reliability score reached 65%, so WorldPulse marks it verified. That means more than one outlet says so, not that it is proven true.
Who reported it
The story so far · 4 reports · · 2 countries✓ Verified Nov 12, 3:44 PM UTC
- Nov 12, 11:56 AM UTCFirst reportEli Lilly breaks ground with China approval for obesity pillbdnews24.com ↗
- Nov 12, 3:44 PM UTC+4 hNovo rival Eli Lilly wins approval for weight-loss pill in Chinacphpost.dk ↗
- Verified: a second independent outlet reported itNov 12, 3:44 PM UTC · +4 h
- Nov 12, 7:16 PM UTC+7 hEli Lilly breaks ground with China approval for obesity pillbdnews24.com (again) ↗
- Nov 12, 10:43 PM UTC+11 h· you’re reading thisGLP-1 weight-loss pills expand to China as US firm wins approvalclichemag.com ↗
Location
Verification Log
No verification data yet
Checks run automatically as new sources are ingested.
Reliability
Reliability ScoreVery high
81%Independent outlets2
Statusverified
AI checknone yet
Community flags0
Score bands
Very high80–100%
A highly rated outlet, or several independent outletsHigh60–79%
One well-rated outlet so farModerate40–59%
A lower-rated or state-run outlet, or one report of something seriousLow20–39%
A low-rated outlet on a serious or sensitive storyVery low0–19%
Treat it as unconfirmedWhat moves the score
◎
Outlet ratingThe outlet’s rating in WorldPulse’s list of sources starts the score
⇄
Independent outletsEach further outlet that reports the story closes 40% of the gap to 98%
±
Report detailsA few points either way: a summary and a place add a little; state-run outlets on conflict, politics or security, and single reports marked high or critical, lose some
Not in the score: AI checks and reader flags. Verified is separate: two or more independent outlets and a score of at least 65%.
Very high · How we score this
Risk Score
low risk